Cancer concerns with topical immunomodulators in atopic dermatitis: Overview of data and recommendations to clinicians

Tejesh Patel, Sarah C. Greer, Robert B. Skinner

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

The topical immunomodulators tacrolimus and pimecrolimus were approved for the treatment of atopic dermatitis in 2000 and 2001, respectively. However, on 20 January 2006, the US FDA approved a 'black box' warning for these agents because of concerns regarding a possible link to development of malignancy. These concerns were based upon the known mechanism of action of this drug class, the results of animal studies, and case reports. This article provides an overview of the data that led to the approval by the FDA of a 'black box' warning and concludes that physicians, patients, and caregivers should feel confident about using tacrolimus and pimecrolimus for atopic dermatitis so long as they follow the FDA guidelines.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalAmerican Journal of Clinical Dermatology
Volume8
Issue number4
DOIs
StatePublished - Aug 8 2007

Fingerprint

Drug Labeling
Immunologic Factors
Tacrolimus
Atopic Dermatitis
Caregivers
Neoplasms
Guidelines
Physicians
Pharmaceutical Preparations
pimecrolimus
Therapeutics

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Cancer concerns with topical immunomodulators in atopic dermatitis : Overview of data and recommendations to clinicians. / Patel, Tejesh; Greer, Sarah C.; Skinner, Robert B.

In: American Journal of Clinical Dermatology, Vol. 8, No. 4, 08.08.2007, p. 189-194.

Research output: Contribution to journalReview article

@article{ad5dabed48414392ba3292a03c20a8cc,
title = "Cancer concerns with topical immunomodulators in atopic dermatitis: Overview of data and recommendations to clinicians",
abstract = "The topical immunomodulators tacrolimus and pimecrolimus were approved for the treatment of atopic dermatitis in 2000 and 2001, respectively. However, on 20 January 2006, the US FDA approved a 'black box' warning for these agents because of concerns regarding a possible link to development of malignancy. These concerns were based upon the known mechanism of action of this drug class, the results of animal studies, and case reports. This article provides an overview of the data that led to the approval by the FDA of a 'black box' warning and concludes that physicians, patients, and caregivers should feel confident about using tacrolimus and pimecrolimus for atopic dermatitis so long as they follow the FDA guidelines.",
author = "Tejesh Patel and Greer, {Sarah C.} and Skinner, {Robert B.}",
year = "2007",
month = "8",
day = "8",
doi = "10.2165/00128071-200708040-00001",
language = "English (US)",
volume = "8",
pages = "189--194",
journal = "American Journal of Clinical Dermatology",
issn = "1175-0561",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Cancer concerns with topical immunomodulators in atopic dermatitis

T2 - Overview of data and recommendations to clinicians

AU - Patel, Tejesh

AU - Greer, Sarah C.

AU - Skinner, Robert B.

PY - 2007/8/8

Y1 - 2007/8/8

N2 - The topical immunomodulators tacrolimus and pimecrolimus were approved for the treatment of atopic dermatitis in 2000 and 2001, respectively. However, on 20 January 2006, the US FDA approved a 'black box' warning for these agents because of concerns regarding a possible link to development of malignancy. These concerns were based upon the known mechanism of action of this drug class, the results of animal studies, and case reports. This article provides an overview of the data that led to the approval by the FDA of a 'black box' warning and concludes that physicians, patients, and caregivers should feel confident about using tacrolimus and pimecrolimus for atopic dermatitis so long as they follow the FDA guidelines.

AB - The topical immunomodulators tacrolimus and pimecrolimus were approved for the treatment of atopic dermatitis in 2000 and 2001, respectively. However, on 20 January 2006, the US FDA approved a 'black box' warning for these agents because of concerns regarding a possible link to development of malignancy. These concerns were based upon the known mechanism of action of this drug class, the results of animal studies, and case reports. This article provides an overview of the data that led to the approval by the FDA of a 'black box' warning and concludes that physicians, patients, and caregivers should feel confident about using tacrolimus and pimecrolimus for atopic dermatitis so long as they follow the FDA guidelines.

UR - http://www.scopus.com/inward/record.url?scp=34547579870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547579870&partnerID=8YFLogxK

U2 - 10.2165/00128071-200708040-00001

DO - 10.2165/00128071-200708040-00001

M3 - Review article

C2 - 17645374

AN - SCOPUS:34547579870

VL - 8

SP - 189

EP - 194

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

SN - 1175-0561

IS - 4

ER -